Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity

Journal of Immunology

Volumn 198, Issue 3, 2017, Pages 1308-1319

  Dudhgaonkar, Shailesh ^a   Ranade, Sourabh ^a   Nagar, Jignesh ^a   Subramani, Siva ^a   Prasad, Durga Shiv ^a   Karunanithi, Preethi ^a   Srivastava, Ratika ^a   Venkatesh, Kamala ^a   Selvam, Sabariya ^a   Krishnamurthy, Prasad ^a   Mariappan, T Thanga ^a   Saxena, Ajay ^a   Fan, Li ^a   Stetsko, Dawn K ^a   Holloway, Deborah A ^a   Li, Xin ^a   Zhu, Jun ^a   Yang, Wen Pin ^a   Ruepp, Stefan ^a   Nair, Satheesh ^a   Santella, Joseph ^a   Duncia, John ^a   Hynes, John ^a   McIntyre, Kim W ^a   Carman, Julie A ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 986126; CYTOKINE; DEXAMETHASONE; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHOTRANSFERASE INHIBITOR; PREDNISOLONE; STEROID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; DISEASE ACTIVITY; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUPUS VULGARIS; MOUSE; NONHUMAN; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; PREDNISOLONE; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 85014694772     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600583     Document Type: Conference Paper

References (38)

1. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384.
2. Sims, J. E., and D. E. Smith. 2010. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10: 89-102.
3. Lin, S. C., Y. C. Lo, and H. Wu. 2010. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465: 885-890.
4. Flannery, S., and A. G. Bowie. 2010. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem. Pharmacol. 80: 1981-1991.
5. Picard, C., A. Puel, M. Bonnet, C. L. Ku, J. Bustamante, K. Yang, C. Soudais, S. Dupuis, J. Feinberg, C. Fieschi, et al. 2003. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299: 2076-2079.
6. Ku, C. L., H. von Bernuth, C. Picard, S. Y. Zhang, H. H. Chang, K. Yang, M. Chrabieh, A. C. Issekutz, C. K. Cunningham, J. Gallin, et al. 2007. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J. Exp. Med. 204: 2407-2422.
7. Suzuki, N., S. Suzuki, G. S. Duncan, D. G. Millar, T. Wada, C. Mirtsos, H. Takada, A. Wakeham, A. Itie, S. Li, et al. 2002. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416: 750-756.
8. Thomas, J. A., J. L. Allen, M. Tsen, T. Dubnicoff, J. Danao, X. C. Liao, Z. Cao, and S. A. Wasserman. 1999. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J. Immunol. 163: 978-984.
9. Swantek, J. L., M. F. Tsen, M. H. Cobb, and J. A. Thomas. 2000. IL-1 receptorassociated kinase modulates host responsiveness to endotoxin. J. Immunol. 164: 4301-4306.
10. Wan, Y., H. Xiao, J. Affolter, T. W. Kim, K. Bulek, S. Chaudhuri, D. Carlson, T. Hamilton, B. Mazumder, G. R. Stark, et al. 2009. Interleukin-1 receptorassociated kinase 2 is critical for lipopolysaccharide-mediated posttranscriptional control. J. Biol. Chem. 284: 10367-10375.
11. Koziczak-Holbro, M., C. Joyce, A. Glück, B. Kinzel, M. Müller, C. Tschopp, J. C. Mathison, C. N. Davis, and H. Gram. 2007. IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and Toll-like receptor 7-mediated signaling and gene expression. J. Biol. Chem. 282: 13552-13560.
12. Kawagoe, T., S. Sato, A. Jung, M. Yamamoto, K. Matsui, H. Kato, S. Uematsu, O. Takeuchi, and S. Akira. 2007. Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J. Exp. Med. 204: 1013-1024.
13. Fraczek, J., T. W. Kim, H. Xiao, J. Yao, Q. Wen, Y. Li, J. L. Casanova, J. Pryjma, and X. Li. 2008. The kinase activity of IL-1 receptor-associated kinase 4 is required for interleukin-1 receptor/Toll-like receptor-induced TAK1-dependent NFκB activation. J. Biol. Chem. 283: 31697-31705.
14. Wu, Y. W., W. Tang, and J. P. Zuo. 2015. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol. Sin. 36: 1395-1407.
15. Bennett, L., A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, and V. Pascual. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197: 711-723.
16. Barrat, F. J., T. Meeker, J. Gregorio, J. H. Chan, S. Uematsu, S. Akira, B. Chang, O. Duramad, and R. L. Coffman. 2005. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202: 1131-1139.
17. Gilliet, M., W. Cao, and Y. J. Liu. 2008. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8: 594-606.
18. Avalos, A. M., L. Busconi, and A. Marshak-Rothstein. 2010. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 43: 76-83.
19. Junt, T., and W. Barchet. 2015. Translating nucleic acid-sensing pathways into therapies. Nat. Rev. Immunol. 15: 529-544.
20. Christensen, S. R., J. Shupe, K. Nickerson, M. Kashgarian, R. A. Flavell, and M. J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417-428.
21. Torres-Salido, M. T., J. Cortés-Hernández, X. Vidal, A. Pedrosa, M. Vilardell-Tarrés, and J. Ordi-Ros. 2014. Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. Nephrol. Dial. Transplant. 29: 1740-1749.
22. Guiducci, C., M. Gong, Z. Xu, M. Gill, D. Chaussabel, T. Meeker, J. H. Chan, T. Wright, M. Punaro, S. Bolland, et al. 2010. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465: 937-941.
23. Sun, J., N. Li, K. S. Oh, B. Dutta, S. J. Vayttaden, B. Lin, T. S. Ebert, D. De Nardo, J. Davis, R. Bagirzadeh, et al. 2016. Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use. Sci. Signal. 9: ra3.
24. Koziczak-Holbro, M., A. Glück, C. Tschopp, J. C. Mathison, and H. Gram. 2008. IRAK-4 kinase activity-dependent and -independent regulation of lipopolysaccharide-inducible genes. Eur. J. Immunol. 38: 788-796.
25. McElroy, W. T., Z. Tan, G. Ho, S. Paliwal, G. Li, W. M. Seganish, D. Tulshian, J. Tata, T. O. Fischmann, C. Sondey, et al. 2015. Potent and selective amidopyrazole inhibitors of IRAK4 that are efficacious in a rodent model of inflammation. ACS Med. Chem. Lett. 6: 677-682.
26. Kelly, P. N., D. L. Romero, Y. Yang, A. L. Shaffer, III, D. Chaudhary, S. Robinson, W. Miao, L. Rui, W. F. Westlin, R. Kapeller, and L. M. Staudt. 2015. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J. Exp. Med. 212: 2189-2201.
27. Kondo, M., A. Tahara, K. Hayashi, M. Abe, H. Inami, T. Ishikawa, H. Ito, and Y. Tomura. 2014. Renoprotective effects of novel interleukin-1 receptorassociated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats. Naunyn Schmiedebergs Arch. Pharmacol. 387: 909-919.
28. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, and S. Akira. 2003. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301: 640-643.
29. Kolanowski, S. T., M. C. Dieker, S. N. Lissenberg-Thunnissen, G. M. van Schijndel, S. M. van Ham, and A. ten Brinke. 2014. TLR4-mediated proinflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIF. Innate Immun. 20: 423-430.
30. Barrat, F. J., T. Meeker, J. H. Chan, C. Guiducci, and R. L. Coffman. 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37: 3582-3586.
31. 1 mice. Autoimmunity 46: 419-428.
32. Teichmann, L. L., D. Schenten, R. Medzhitov, M. Kashgarian, and M. J. Shlomchik. 2013. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 38: 528-540.
33. Gurkan, S., A. Cabinian, V. Lopez, M. Bhaumik, J. M. Chang, A. B. Rabson, and P. Mundel. 2013. Inhibition of type I interferon signalling prevents TLR ligandmediated proteinuria. J. Pathol. 231: 248-256.
34. Motojima, M., T. Matsusaka, V. Kon, and I. Ichikawa. 2010. Fibrinogen that appears in Bowman's space of proteinuric kidneys in vivo activates podocyte Toll-like receptors 2 and 4 in vitro. Nephron, Exp. Nephrol. 114: e39-e47.
35. Tsai, P. Y., S. M. Ka, J. M. Chang, H. C. Chen, H. A. Shui, C. Y. Li, K. F. Hua, W. L. Chang, J. J. Huang, S. S. Yang, and A. Chen. 2011. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic. Biol. Med. 51: 744-754.
36. Nanda, S. K., M. Lopez-Pelaez, J. S. C. Arthur, F. Marchesi, and P. Cohen. 2016. Suppression of IRAK1 or IRAK4 catalytic activity, but not type I IFN signaling, prevents lupus nephritis in mice expressing a ubiquitin binding-defective mutant of ABIN1. J. Immunol. 197: 4266-4273.
37. Furie, R., J. Merrill, V. Werth, M. Khamashta, K. Kalunian, P. Brohawn, G. Illei, J. Drappa, L. Wang, and S. Yoo. 2015. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheumatol. 67(Suppl. 10):3865-3868.
38. von Bernuth, H., C. Picard, A. Puel, and J. L. Casanova. 2012. Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans. Eur. J. Immunol. 42: 3126-3135.